
    
      A phase 2b, randomized, double-blind, placebo-controlled, multicenter study of subjects with
      sickle cell disease (SCD; homozygous sickle hemoglobin [HbSS], sickle-β0 [HbSB0] thalassemia,
      or sickle-β+ [HbSB+] thalassemia) to evaluate the safety and efficacy of the
      phosphodiesterase type 9 (PDE9) inhibitor, IMR-687, administered once daily (qd) for 52
      weeks.
    
  